Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Rating) hit a new 52-week high on Friday . The company traded as high as $26.08 and last traded at $25.72, with a volume of 136010 shares changing hands. The stock had previously closed at $23.60.
Wall Street Analyst Weigh In
Several analysts have issued reports on PTGX shares. StockNews.com downgraded Protagonist Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, March 24th. HC Wainwright boosted their price objective on Protagonist Therapeutics from $33.00 to $38.00 and gave the stock a “buy” rating in a report on Thursday, March 16th. Finally, JMP Securities cut their price objective on Protagonist Therapeutics from $31.00 to $28.00 and set a “market outperform” rating on the stock in a report on Thursday, March 16th.
Protagonist Therapeutics Stock Up 5.1 %
The stock has a market cap of $1.28 billion, a P/E ratio of -9.54 and a beta of 1.96. The business has a 50-day simple moving average of $21.47 and a 200-day simple moving average of $14.49.
Institutional Investors Weigh In On Protagonist Therapeutics
Protagonist Therapeutics Company Profile
Protagonist Therapeutics, Inc a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
- Get a free copy of the StockNews.com research report on Protagonist Therapeutics (PTGX)
- MarketBeat Week in Review – 5/1 – 5/5
- It’s Time To Check Into Booking.Com
- Shopify Delivers Growth And Efficiency; Shares Surge
- Advanced Micro Devices Bullish Reversal Is Still In Play
- Broadcom Shares Trade In Tight Range Ahead Of Q2 Earnings Report
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.